IMRX Share Price Performance
US$6.05
3.60 (146.94%)
Price US$6.05
Share PriceUS$6.05
Immuneering Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
IMRX Community Narratives
There are no narratives available yet.
Immuneering Corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.98
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Immuneering Corporation Competitors
Snowflake Analysis
About IMRX
- Founded
- 2008
- Employees
- 54
- CEO
- WebsiteView website
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. In the last year, the market has climbed 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›